We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00681369
First Posted: May 21, 2008
Last Update Posted: January 24, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile

Condition
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluate Faslodex therapeutic strategy and treatment duration [ Time Frame: At the end of the study ]
  • Describe the characteristics of patients treated with Faslodex [ Time Frame: At the end of the study ]

Enrollment: 217
Study Start Date: May 2007
Study Completion Date: June 2007
Groups/Cohorts
1
Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hospital sample
Criteria

Inclusion Criteria:

  • Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00681369


Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Alain FLINOIS TNS Healthcare - France138, avenue Marx Dormoy92120 Montrouge
  More Information

Responsible Party: Francisco Sapunar - Medical Science Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT00681369     History of Changes
Other Study ID Numbers: NIS-OFR-FAS-2007/1
First Submitted: May 20, 2008
First Posted: May 21, 2008
Last Update Posted: January 24, 2011
Last Verified: January 2011

Keywords provided by AstraZeneca:
breast cancer
fulvestrant
longitudinal study
France

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Fulvestrant
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs